Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Up 34.6% in August

Jasper Therapeutics, Inc. (NASDAQ:JSPRWGet Free Report) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 21,400 shares, a growth of 34.6% from the August 15th total of 15,900 shares. Based on an average daily trading volume, of 4,300 shares, the days-to-cover ratio is presently 5.0 days.

Jasper Therapeutics Price Performance

JSPRW traded up $0.01 during midday trading on Monday, hitting $0.20. 3,853 shares of the company traded hands, compared to its average volume of 20,290. The company’s 50-day moving average is $0.21 and its 200 day moving average is $0.20. Jasper Therapeutics has a 52 week low of $0.04 and a 52 week high of $0.38.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

See Also

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.